Ann: NEU confirms primary endpoints for Phase 3 trial in PMS, page-55

I respectfully disagree. - imo end of 2026 is closer to the mark, for a few key reasons;

1) they have already been planing this for months, not waiting
2) in conjunction with (1), imo will be much easier to enroll and begin given their current success, partnerships and experience
3) the agreed endpoints align nicely with not only the strengths of nzz, but also previously reported results. I feel this is also to neurens advantage

imo 2027 would be a worst case scenario and only occur I case of fda delay or unexpected delay. Last quarter 2026 is my estimate